^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ubamatamab (REGN4018)

    i
    Other names: REGN4018, REGN 4018, REGN-4018
    Company:
    Regeneron
    Drug class:
    CD3 agonist, MUC16 inhibitor
    Related drugs:
    8d
    RegeNovar: Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=43, Not yet recruiting, ARCAGY/ GINECO GROUP
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated) • CD4 (CD4 Molecule)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018)
    11d
    Gineco-ov133b: REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy. (2025-524232-20-00)
    P1/2, N=43, Not yet recruiting, Asso De Recherche Cancers Gynecologiques
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018) • Neupogen (filgrastim)
    1m
    R4018-ONC-1721: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (clinicaltrials.gov)
    P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Feb 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Libtayo (cemiplimab-rwlc) • Actemra IV (tocilizumab) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    3ms
    Compassionate Use of Ubamatamab (clinicaltrials.gov)
    P=N/A, N=0, Available, Regeneron Pharmaceuticals
    New trial
    |
    ubamatamab (REGN4018)
    3ms
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)
    10ms
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Regeneron Pharmaceuticals
    New P2 trial
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)
    10ms
    R5668-ONC-1938: A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab (clinicaltrials.gov)
    P1/2, N=612, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Apr 2027 --> Nov 2027
    Trial completion date
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767) • ubamatamab (REGN4018) • Kevzara (sarilumab) • REGN5668
    11ms
    Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes. (PubMed, JCO Precis Oncol)
    MUC16 is frequently detected in ES and MRTs. Ubamatamab is an encouraging anti-MUC16 therapy, demonstrating clinical efficacy. Ongoing trials (ClinicalTrials.gov identifier: NCT06444880) are evaluating ubamatamab in other rare MUC16-positive tumors.
    Retrospective data • Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    ubamatamab (REGN4018)
    11ms
    R4018-ONC-1721: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (clinicaltrials.gov)
    P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Libtayo (cemiplimab-rwlc) • Actemra IV (tocilizumab) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    1year
    Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=220, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    Avastin (bevacizumab) • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    1year
    Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=220, Not yet recruiting, Regeneron Pharmaceuticals | Trial completion date: Apr 2028 --> Dec 2028 | Trial primary completion date: Apr 2028 --> Dec 2028
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    Avastin (bevacizumab) • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    over1year
    Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=220, Not yet recruiting, Regeneron Pharmaceuticals
    New P2 trial
    |
    Avastin (bevacizumab) • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767) • ubamatamab (REGN4018) • Kevzara (sarilumab)